Home Headline News Human Health and Life Research ‘Human Glycome Project’

Human Health and Life Research ‘Human Glycome Project’

(PRNewsFoto/New England Biolabs, Inc.)

The Human Glycome Project,  Genos®, New England Biolabs® (NEB®) and Waters™ Corporation today announced a collaboration to accelerate glycomics research by providing goods and services critical to glycan analysis.

Launched in October 2018, the Human Glycome Project is a global initiative to map the structure and function of human glycans. The completion of the human genome project opened multiple new opportunities to study and understand human health, but it also led to the realization that the genome is only one of the elements that controls life. There are multiple additional layers of complexity that exist, one of which is protein glycosylation (“glycans”). Glycans are relevant to our understanding of all major diseases, but due to their structural complexity and analytical challenges, knowledge of glycans lags significantly behind that of DNA and proteins.

Just weeks before the 2nd Meeting of the Human Glycome Project, taking place on June 19th and 20th in Split, Croatia, Genos, NEB and Waters have agreed to combine forces to support this important scientific project. The agreements between Genos, NEB and Waters will enable the analysis of glycans in 10,000 human samples per year, originating from some of the best characterized clinical and epidemiological cohorts in the world. Waters and NEB will provide pro bono reagents and consumables, while Genos will perform the required analyses.

Gordan Lauc, Founder and CEO of Genos: “As a Co-Director of the Human Glycome Project I am thrilled that the support from Genos, NEB and Waters will enable us to add glycan data to some very exciting clinical and epidemiological studies. We already know that glycans have significant predictive power in inflammatory and cardiometabolic disorders, but this is probably only a tip of an iceberg of glycan biomarker potential. At the same time, I am very proud that Genos has been recognized as a site where these challenging analyses can be performed.”

Chris Taron, Scientific Director of Protein Modification Research at NEB added “Decades of glycobiology research point to glycans playing important roles in both normal health and in disease.  Systematic exploration of the human glycome in large clinical cohorts has the potential to help write a new chapter in translational medicine.  We are very proud to be working with Genos and Waters to support this important initiative”.

Diane M. Diehl, Ph.D., Senior Director, Pharmaceutical & Biomedical Research, Waters Corporation, “Changes in the glycosylation of proteins is a fundamental characteristic of many diseases, such as cancer. We at Waters believe that improved understanding of glycomics through advanced analytical characterization is critically important for biomedical research and to the patients that will potentially benefit from this research. Our ACQUITY UPLC™ technology and GlycoWorks RapiFluor-MS™ sample preparation kits enhance glycan sensitivity for improved analytical speed and resolving power. Waters is excited to support the efforts of the Human Glycome Project.”

The selection of the studies, which will be supported through December 2021, will be determined by the Steering Committee of the Human Glycome Project, and the results of all sample analyses will be made available to the scientific community through Human Glycome Project depositories that are being developed separately in collaboration with the Swiss Institute of Bioinformatics.

Previous articleBoeing Aerospace and Defense Market To Reach $8.7 Trillion
Next articleSterile Injectables Manufacturing Facility In Spain By LSNE
Ivy Heffernan, student of Economics at Buckingham University. Junior Analyst at HeffX and experienced marketing director.